EcoDrugPlus

Cytochrome P450 19a1-Like

Ensembl ID : ENSORLG00000002949
Gene Symbol: LOC101174651
4 Cross references
249 Possible Orthologues:

Cytochrome P450 19b

Ensembl ID : ENSORLG00000005548
Gene Symbol: CYP19B
3 Cross references
244 Possible Orthologues:

Cytochrome P450 3a30

Ensembl ID : ENSORLG00000003976
Gene Symbol: LOC101155538
3 Cross references
520 Possible Orthologues:

Cytochrome P450 3a30

Ensembl ID : ENSORLG00000003987
Gene Symbol: LOC101157802
3 Cross references
522 Possible Orthologues:

Cytochrome P450 3a40

Ensembl ID : ENSORLG00000019560
Gene Symbol: CYP3A40
3 Cross references
541 Possible Orthologues:

Cytochrome P450 3a40

Ensembl ID : ENSORLG00000004010
Gene Symbol: LOC101158047
3 Cross references
522 Possible Orthologues:

Cytochrome P450 3a56

Ensembl ID : ENSORLG00000003970
Gene Symbol: LOC101155293
3 Cross references
523 Possible Orthologues:

Cytochrome P450, Family 26, Subfamily A, Polypeptide 1

Ensembl ID : ENSORLG00000014516
Gene Symbol: CYP26A1
3 Cross references
194 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A

Ensembl ID : ENSORLG00000019618
Gene Symbol: CYP3A
3 Cross references
541 Possible Orthologues:

Delta-Type Opioid Receptor

Ensembl ID : ENSORLG00000024140
Gene Symbol: LOC101159953
3 Cross references
197 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSORLG00000008631
Gene Symbol: LOC101166984
4 Cross references
190 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSORLG00000019263
Gene Symbol: LOC101155899
4 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).